Analyse Hepion Pharmaceuticals, Inc. (HEPA) — Kairos Score 62/100

À propos de Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC), metabolic liver diseases, and chronic liver diseases in the United States. It developed Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as well as preclinical experiments of Rencofilstat reflects decreased liver fibrosis; liver inflammation; liver tumor burden; and titers of HBV, HCV, and HDV. It also operates as a biotech research development company. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Morristown, New Jersey.

Informations clés

🕴️ Activité des initiés (90 jours)

1 transactions — 1 achats et 0 ventes déclarés par les dirigeants de Hepion Pharmaceuticals, Inc..

🏦 Hedge Funds

0 fonds institutionnels déclarent une position sur HEPA dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

3 articles récents sur HEPA.

• Hepion Pharmaceuticals Receives Positive FDA Response on GV104 in Gambling Disorder, a Condition With No Approved Medication
• Hepion Pharmaceuticals Completes Acquisition of Gravitas Life Sciences and Provides Corporate Update

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.